Related Experiment Video
Updated: May 23, 2026
11:24
Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice
Published on: February 10, 2018
[Hepatic encephalopathy and liver transplantation]
Imre Fehérvári1, Balázs Nemes, Dénes Görög
1Semmelweis Egyetem Transzplantációs és Sebészeti Klinika, Budapest. drfehervariimre@t-online.hu
Magyar Sebeszet
|April 20, 2012
Summary
Liver cirrhosis complications like hepatic encephalopathy (HE) are deadly. Current treatments show limited effectiveness, highlighting the need for new guidelines to improve survival, especially post-liver transplantation.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Liver cirrhosis affects 6500-7000 individuals annually in Hungary.
- Hepatic encephalopathy (HE) is a common, serious complication of liver cirrhosis.
- Emerging evidence links HE severity to systemic inflammation, challenging the traditional ammonia toxicity theory.
Purpose of the Study:
- To review and analyze the latest treatment modalities for hepatic encephalopathy.
- To evaluate the efficacy of current evidence-based treatments for HE.
- To identify the need for a consensus guideline for HE management.
Main Methods:
- Systematic literature review of recent findings on HE treatment.
- Analysis of evidence-based treatments including metronidazole, neomycin, disaccharides, and rifaximine.
- Assessment of treatment efficacy based on clinical studies and evidence grading.
Main Results:
- Conventional treatments (metronidazole, neomycin, disaccharides) demonstrated only partial effectiveness.
- Rifaximine shows Grade I evidence support but is costly.
- No generally accepted treatment guideline for HE was identified.
Conclusions:
- Current therapeutic options for hepatic encephalopathy are limited in efficacy.
- The high cost of effective treatments like rifaximine presents a challenge.
- There is an urgent need to develop a consensus guideline for HE treatment to improve patient survival, particularly after liver transplantation.
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...